仟源医药：股东翁占国计划减持公司股份不超过约768万股

Summary of Key Points Core Viewpoint - QianYuan Pharmaceutical (SZ 300254) announced a share reduction plan by a major shareholder, which may impact the stock's performance and investor sentiment [1]. Group 1: Shareholder Actions - Mr. Weng Zhangguo, a shareholder holding approximately 15.77 million shares (6.16% of total shares), plans to reduce his holdings by up to 7.68 million shares (up to 3% of total shares) within three months from the announcement date [1]. - The reduction will occur through centralized bidding and block trading, with specific limits on the number of shares that can be sold in any 90-day period [1]. Group 2: Revenue Composition - For the year 2024, QianYuan Pharmaceutical's revenue composition is as follows: - Pharmaceutical manufacturing: 96.68% - DNA gene preservation and prenatal environment testing services: 1.93% - Health food: 0.79% - Other businesses: 0.51% - Commercial: 0.1% [1]. Group 3: Market Capitalization - As of the latest report, QianYuan Pharmaceutical has a market capitalization of 2.8 billion yuan [2].